According to one researcher, the instrument running an ion mobility-based workflow offers speed and sensitivity gains of up to 10-fold compared to other methods.
The full analysis has yet to be completed, but initial findings from the breast cancer study appear positive as researchers begin enrolling for a third trial.
The scientists hope to incorporate the method, which can measure endogenous peptides at zeptomolar concentrations, in clinical trials starting next year.
Additional studies and reanalyses can reclassify variants of unknown significance, speakers at the National Society of Genetic Counselors meeting said.
This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.
